Show simple item record

dc.contributor.authorVilos C.
dc.contributor.authorConstandil L.
dc.contributor.authorRodas P.I.
dc.contributor.authorCantin M.
dc.contributor.authorZepeda K.
dc.contributor.authorHerrera N.
dc.contributor.authorVelasquez L.A.
dc.date.accessioned2020-09-02T22:30:26Z
dc.date.available2020-09-02T22:30:26Z
dc.date.issued2014
dc.identifier10.2147/DDDT.S60444
dc.identifier.citation8, , 651-666
dc.identifier.issn11778881
dc.identifier.urihttps://hdl.handle.net/20.500.12728/6585
dc.descriptionDespite the high number of antibiotics used for the treatment of infectious disease in animals, the development of slow release formulations presents a significant challenge, particularly in using novel biomaterials with low cost. In this report, we studied the pharmacokinetics, toxicity, and therapeutic activity of ceftiofur-PHBV (ceftiofur-poly(3-hydroxybutyrate-co-3-hydroxyvalerate)) in rats. The pharmacokinetic study demonstrated a sustained release of ceftiofur into the bloodstream, with detectable levels over the minimum inhibitory concentration for at least 17 days after a single intramuscular injection of ceftiofur-PHBV (10 mg/kg weight). In addition, the toxicological evaluation of biochemical, hematological, and coagulation blood parameters at the therapeutic dose demonstrated the safety of ceftiofur-PHBV, with no adverse effects. In addition, ceftiofur-PHBV exhibited a therapeutic effect for a longer time period than the nonencapsulated ceftiofur in rats challenged with Salmonella Typhimurium. The slow release of ceftiofur from the ceftiofur-PHBV, its low toxicity in the blood parameters evaluated, and the efficacy in the rats infected with Salmonella Typhimurium make ceftiofur-PHBV a strong candidate for biotechnological applications in the veterinary industry. © 2014 Vilos et al.
dc.language.isoen
dc.publisherDove Medical Press Ltd.
dc.subjectBlood parameters
dc.subjectDrug delivery
dc.subjectMicroparticles
dc.subjectRat infection model
dc.subjectSalmonella typhimurium
dc.subjectceftiofur
dc.subjectcopolymer
dc.subjectpoly(3 hydroxybutyrate co 3 hydroxyvalerate)
dc.subjectunclassified drug
dc.subjectceftiofur
dc.subjectcephalosporin derivative
dc.subjectpoly(3-hydroxybutyrate)-co-(3-hydroxyvalerate)
dc.subjectpolyester
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectarea under the curve
dc.subjectarticle
dc.subjectcontrolled study
dc.subjectdrug efficacy
dc.subjectdrug half life
dc.subjectdrug safety
dc.subjectdrug synthesis
dc.subjectencapsulation
dc.subjectmale
dc.subjectmaximum plasma concentration
dc.subjectminimum inhibitory concentration
dc.subjectnonhuman
dc.subjectrat
dc.subjectSalmonella typhimurium
dc.subjectsalmonellosis
dc.subjectsustained drug release
dc.subjecttime to maximum plasma concentration
dc.subjecttoxicity testing
dc.subjectanimal
dc.subjectdisease model
dc.subjectdose response
dc.subjectdrug effects
dc.subjecterythrocyte
dc.subjectintramuscular drug administration
dc.subjectmicrobial sensitivity test
dc.subjectmicrobiology
dc.subjectSalmonella enterica serovar Typhimurium
dc.subjectSalmonella Infections
dc.subjectSprague Dawley rat
dc.subjectstructure activity relation
dc.subjectAnimals
dc.subjectCephalosporins
dc.subjectDisease Models, Animal
dc.subjectDose-Response Relationship, Drug
dc.subjectErythrocytes
dc.subjectInjections, Intramuscular
dc.subjectMale
dc.subjectMicrobial Sensitivity Tests
dc.subjectPolyesters
dc.subjectRats
dc.subjectRats, Sprague-Dawley
dc.subjectSalmonella Infections
dc.subjectSalmonella typhimurium
dc.subjectStructure-Activity Relationship
dc.titleEvaluation of ceftiofur-PHBV microparticles in rats
dc.typeArticle


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record